These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26660063)

  • 1. Neuroleptic-induced Parkinsonism: Clinicopathological study.
    Shuaib UA; Rajput AH; Robinson CA; Rajput A
    Mov Disord; 2016 Mar; 31(3):360-5. PubMed ID: 26660063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical parkinsonism in dementia patients with substantia nigra Lewy bodies.
    Ala TA; Yang KH; Sung JH; Frey WH
    J Neural Transm (Vienna); 1999; 106(1):47-57. PubMed ID: 10195334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyotrophic lateral sclerosis with dementia showing clinical parkinsonism and severe degeneration of the substantia nigra: report of an autopsy case.
    Shintaku M; Oyanagi K; Kaneda D
    Neuropathology; 2007 Jun; 27(3):295-9. PubMed ID: 17645246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigral pathology and parkinsonian signs in elders without Parkinson disease.
    Buchman AS; Shulman JM; Nag S; Leurgans SE; Arnold SE; Morris MC; Schneider JA; Bennett DA
    Ann Neurol; 2012 Feb; 71(2):258-66. PubMed ID: 22367997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs.
    Bocola V; Fabbrini G; Sollecito A; Paladini C; Martucci N
    J Neurol Neurosurg Psychiatry; 1996 Feb; 60(2):213-6. PubMed ID: 8708659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcranial sonographic findings may predict prognosis of gastroprokinetic drug-induced parkinsonism.
    Oh YS; Kwon DY; Kim JS; Park MH; Berg D
    Parkinsonism Relat Disord; 2018 Jan; 46():36-40. PubMed ID: 29111425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study.
    Avorn J; Bohn RL; Mogun H; Gurwitz JH; Monane M; Everitt D; Walker A
    Am J Med; 1995 Jul; 99(1):48-54. PubMed ID: 7598142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy.
    Berg D; Jabs B; Merschdorf U; Beckmann H; Becker G
    Biol Psychiatry; 2001 Sep; 50(6):463-7. PubMed ID: 11566164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
    Lim TT; Ahmed A; Itin I; Gostkowski M; Rudolph J; Cooper S; Fernandez HH
    Int J Neurosci; 2013 Mar; 123(3):170-4. PubMed ID: 23078283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does levodopa accelerate the pathologic process in Parkinson disease brain?
    Parkkinen L; O'Sullivan SS; Kuoppamäki M; Collins C; Kallis C; Holton JL; Williams DR; Revesz T; Lees AJ
    Neurology; 2011 Oct; 77(15):1420-6. PubMed ID: 21917769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-nonresponsive Lewy body parkinsonism: clinicopathologic study of two cases.
    Mark MH; Sage JI; Dickson DW; Schwarz KO; Duvoisin RC
    Neurology; 1992 Jul; 42(7):1323-7. PubMed ID: 1620341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases.
    Rajput AH; Rozdilsky B; Hornykiewicz O; Shannak K; Lee T; Seeman P
    Arch Neurol; 1982 Oct; 39(10):644-6. PubMed ID: 6127066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations.
    Rajput AH; Rajput ML; Robinson CA; Rajput A
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1232-7. PubMed ID: 26372624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia.
    Silver M; Factor SA
    Parkinsonism Relat Disord; 2013 Aug; 19(8):758-60. PubMed ID: 23632325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is levodopa toxic to human substantia nigra?
    Rajput AH; Fenton Me; Birdi S; Macaulay R
    Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tardive parkinsonism in a bipolar patient: post-mortem examination supports a physiological rather than pathological dysfunction.
    Won MS; Mikos A; Hurd M; Fernandez H; Eskin T; Romrell J; Okun MS
    Neurocase; 2008; 15(1):66-9. PubMed ID: 19235627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathology of parkinsonism in patients with pure Alzheimer's disease.
    Horvath J; Burkhard PR; Herrmann FR; Bouras C; Kövari E
    J Alzheimers Dis; 2014; 39(1):115-20. PubMed ID: 24121968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic Characteristics of Parkinson's Disease Induced by Neuroleptic Drugs, Based on a Functional Neuroimaging Diagnosis.
    Tachibana K; Matsuura K; Shindo A; Matsuyama H; Ii Y; Taniguchi A; Tomimoto H
    Intern Med; 2020; 59(4):485-490. PubMed ID: 32062624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
    Schneider JS
    Pharmacol Biochem Behav; 1989 Sep; 34(1):193-6. PubMed ID: 2576311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.